Treatment Options for Intermediate Poor Risk Renal Cell Carcinoma

This chapter discusses the treatment options for patients with intermediate poor risk renal cell carcinoma (RCC), including the use of epilimumab with nivolumab as a double immunotherapy combo and the factors to consider when choosing between epinevo and an IOTKI. It also covers second line treatment options and the side effects of veg FTKI.